AdvisorNet Financial Inc Invests $134,000 in Cencora, Inc. (NYSE:COR)

AdvisorNet Financial Inc acquired a new stake in Cencora, Inc. (NYSE:CORFree Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 550 shares of the company’s stock, valued at approximately $134,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COR. Vanguard Group Inc. bought a new position in shares of Cencora in the fourth quarter valued at approximately $4,212,508,000. PNC Financial Services Group Inc. bought a new position in Cencora in the 4th quarter worth $51,339,000. Los Angeles Capital Management LLC bought a new position in Cencora in the 1st quarter worth $45,692,000. Ferguson Wellman Capital Management Inc. acquired a new position in Cencora during the 1st quarter worth $32,609,000. Finally, Czech National Bank bought a new stake in Cencora during the first quarter valued at about $7,079,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Robert P. Mauch sold 57,564 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the completion of the sale, the chief operating officer now owns 24,412 shares in the company, valued at approximately $5,739,017.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Cencora news, CEO Steven H. Collis sold 10,754 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the transaction, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $67,702,698.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Robert P. Mauch sold 57,564 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $235.09, for a total value of $13,532,720.76. Following the completion of the sale, the chief operating officer now owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,956,675 shares of company stock worth $422,352,056. Corporate insiders own 15.80% of the company’s stock.

Cencora Price Performance

NYSE:COR opened at $237.36 on Thursday. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. The company has a 50-day moving average of $229.58 and a 200-day moving average of $227.67. Cencora, Inc. has a 52 week low of $171.65 and a 52 week high of $246.75. The company has a market capitalization of $47.34 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 1.66 and a beta of 0.48.

Cencora (NYSE:CORGet Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The firm had revenue of $68.41 billion during the quarter, compared to analysts’ expectations of $70.60 billion. During the same quarter last year, the company earned $3.50 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were issued a dividend of $0.51 per share. The ex-dividend date was Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.86%. Cencora’s payout ratio is presently 22.32%.

Analyst Ratings Changes

Several research firms recently weighed in on COR. Robert W. Baird boosted their price objective on Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Citigroup raised their price objective on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Finally, StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $233.90.

Check Out Our Latest Research Report on COR

Cencora Company Profile

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Featured Stories

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.